Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma
LR de Brito, MA Batey, Y Zhao, MS Squires… - Leukemia research, 2011 - Elsevier
BACKGROUND: Fibroblast growth factor receptor 3 (FGFR3) is up-regulated as a result of
the t (4; 14)(p16; q32) translocation that occurs in up to 20% of multiple myeloma (MM)
patients. Recent studies have demonstrated that up-regulation of FGFR3 promotes cell
survival, growth and drug resistance in malignant plasma cells, both in vitro and in vivo.
Therefore, inhibition of FGFR3 signalling is potential target for the chemotherapeutic
intervention in t (4; 14) MM. METHODS: Small molecule receptor tyrosine kinase inhibitors …
the t (4; 14)(p16; q32) translocation that occurs in up to 20% of multiple myeloma (MM)
patients. Recent studies have demonstrated that up-regulation of FGFR3 promotes cell
survival, growth and drug resistance in malignant plasma cells, both in vitro and in vivo.
Therefore, inhibition of FGFR3 signalling is potential target for the chemotherapeutic
intervention in t (4; 14) MM. METHODS: Small molecule receptor tyrosine kinase inhibitors …